The Institute has a strong pedigree in understanding the fundamental mechanisms that underpin the success of vaccination and in the development of novel vaccines and their mode of action.

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...

Bristol-Myers Squibb has acquired rights to an “armed virus” targeting cancer from UK biotech, PsiOxus Therapeutics, worth more than $900 million if the project is successful. BMS will pay ...